HighCape Partners
16
9M
8
1.45
5
0.50
2
- Stages of investment
- Areas of investment
Summary
The leading representative office of defined VC is situated in the Baltimore. The company was established in North America in United States.
This organization was formed by Kevin Rakin, Matt Zuga, Matt Zuga.
Speaking about the real fund results, this VC is 18 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2017. The top amount of exits for fund were in 2019. The fund is generally included in less than 2 deals every year. This HighCape Partners works on 16 percentage points less the average amount of lead investments comparing to the other organizations. The common things for fund are deals in the range of 5 - 10 millions dollars.
The typical case for the fund is to invest in rounds with 2-3 participants. Despite the HighCape Partners, startups are often financed by MVM Life Science Partners, Connecticut Innovations, XSeed Capital. The meaningful sponsors for the fund in investment in the same round are MVM Life Science Partners, Connecticut Innovations, Stonehenge Capital. In the next rounds fund is usually obtained by MVM Life Science Partners, Springfield Investments, Robert Bosch Venture Capital.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has exact preference in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Wellness, Fitness. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Zipline Medical, Cybrexa Therapeutics, Aziyo Biologics
Investments analytics
Analytics
- Total investments
- 16
- Lead investments
- 5
- Exits
- 2
- Rounds per year
- 1.45
- Follow on index
- 0.50
- Investments by industry
- Biotechnology (11)
- Health Care (9)
- Medical (6)
- Medical Device (5)
- Therapeutics (5) Show 12 more
- Investments by region
-
- United States (16)
- Peak activity year
- 2017
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Avg. valuation at time of investment
- 29M
- Group Appearance index
- 0.88
- Avg. company exit year
- 18
- Avg. multiplicator
- 2.52
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Alphina Therapeutics | 15 Dec 2020 | Biotechnology, Health Care, Life Science | Seed | United States, Connecticut, Westport | |
| Cybrexa Therapeutics | 21 Jun 2019 | Biotechnology, Pharmaceutical, Therapeutics | Early Stage Venture | 13M | United States, Connecticut, New Haven |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.